{
    "nct_id": "NCT06003426",
    "official_title": "A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis",
    "inclusion_criteria": "Inclusion Criteria\n\n* Subjects with IPF aged â‰¥ 40 years at the time of signing the informed consent.\n* Diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia.\n* If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening.\n* If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.\n* Women who are of childbearing potential must have a highly effective form of contraception and must provide a negative urine/serum pregnancy test.\n* Men who are sexually active with women of childbearing potential agree to use male barrier contraception.\n\nExclusion Criteria\n\n* History of stroke or transient ischemic attack within 3 months prior to screening.\n* Participants who exhibit symptoms of heart failure at rest.\n* Participants who have a current malignancy or a previous malignancy with less than 2 years free of recurrence or a biopsy that is suspicious for malignancy and the possibility of malignancy cannot be reasonably excluded following additional clinical, laboratory, or other diagnostic evaluations.\n* Other protocol-defined Inclusion/Exclusion criteria apply.\nHealthy volunteers allowed\nMust have minimum age of 40 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}